Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07553442 | A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran | PHASE2 | RECRUITING | 93 | — | — | Apr 27, 2026 | Oct 1, 2028 | May 14, 2026 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| ALN-AGT1 RVR | EXPERIMENTAL | Participants will be administered a single dose of zilebesiran followed by a single dose of ALN-AGT01 RVR. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered a single dose of zilebesiran followed by a single dose of placebo. |
| Name | Type | Description |
|---|---|---|
| ALN-AGT01 RVR | DRUG | ALN-AGT01 RVR will be administered subcutaneously (SC) |
| Placebo | DRUG | Placebo will be administered SC |
| Zilebesiran | DRUG | Zilebesiran will be administered SC |
Part A: Inclusion Criteria * Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg * Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications Part B: Inclusion Criteria...